; (3) a summary of any ongoing Federal activities related to the identification, understanding, and mitigation of such potential risks; (4) the identification of any potential gaps, whether current or anticipated, related to such roles, responsibilities, and capabilities; and (5) recommendations to improve Federal efforts to identify, prepare for, and mitigate such potential vulnerabilities. (c) Reports (1) National Academies report Not later than 2 years after the date of the contract under subsection (a), the National Academies shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the study conducted pursuant to subsection (a). (2) HHS report Not later than 1 year after the issuance of the report required under paragraph (1), the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report detailing actions taken to mitigate and monitor risks to health security posed by misuse of artificial intelligence, as detailed in the report under paragraph (1). V Preventing drug shortages 501. Improving notification procedures in case of increased demand for critical drugs (a) In general Section 506C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c ) is amended— (1) in the section heading, by striking Discontinuance or interruption in the production of life-saving drugs and inserting Notification of issues affecting domestic supply of critical drugs ; (2) by striking subsections (a), (b), and (c), and inserting the following: (a) Notification required (1) In general A manufacturer of a covered drug shall notify the Secretary, in accordance with subsection (b), of— (A) (i) a permanent discontinuance in the manufacture of the drug or an interruption of the manufacture of the drug that is likely to lead to a meaningful disruption in the supply of such drug in the United States